Temasek weighs sale of Advanced MedTech, likely valued at about $1bn

Temasek Holdings is considering selling Advanced MedTech, multiple sources told Reuters on Monday, after the medical devices firm, fully-owned by the Singaporean state investor, received interest from suitors including buyout funds.

Two investment banks have been hired to launch a sale process for Singapore-headquartered MedTech, which could be valued at roughly $1 billion, two of the sources said.

All the sources declined to be named as news of the sale process has not been made public.

Get the week’s top news delivered directly to your inbox – Sign up for our newsletter

A Temasek spokesperson declined comment, while there was no immediate comment from an external spokesperson for Advanced MedTech.

Temasek is a global investment company with a net portfolio value of S$381 billion (US$283b) as at 31 March 2021. Headquartered in Singapore, it has 13 offices in 9 countries around the world.

The Temasek Charter defines Temasek’s three roles as an Investor, Institution and Steward, which shape its ethos to do well, do right, and do good. As a provider of catalytic capital, it seeks to enable solutions to key global challenges.

With sustainability at the core of all Temasek does, it actively seeks sustainable solutions to address present and future challenges, as it captures investible opportunities to bring about a sustainable future for all.

Source: Reuters

Can’t stop reading? Read more